AAAAAA
Results:
1-22
|
Results: 22
Authors:
MEGANCK G
MOERMAN P
DESCHRIJVER D
BERTELOOT P
VERGOTE I
Citation: G. Meganck et al., A NON-DIPLOID, SMALL-CELL CARCINOMA OF THE OVARY OF THE HYPERCALCEMICTYPE, International journal of gynecological cancer, 8(5), 1998, pp. 430-433
Authors:
NEVEN P
VERGOTE I
Citation: P. Neven et I. Vergote, CONTROVERSIES REGARDING TAMOXIFEN AND UTERINE CARCINOMA, Current opinion in obstetrics & gynecology, 10(1), 1998, pp. 9-14
Authors:
VERGOTE I
NEVEN P
VANDERICK G
VANDAM P
VANBELLE Y
DESUTTER P
DEPRINS F
DEMUYLDER X
CLAERHOUT J
CAMPO R
ALBERTYN G
Citation: I. Vergote et al., TAMOXIFEN AND THE UTERUS, European journal of cancer, 34, 1998, pp. 1-3
Authors:
TIMMERMAN D
DEPREST J
BOURNE T
VANDENBERGHE I
COLLINS WP
VERGOTE I
Citation: D. Timmerman et al., SALINE INFUSION SONOGRAPHY (SIS) OR OFFICE HYSTEROSCOPY - WHICH ONE IS THE BEST - A PROSPECTIVE RANDOMIZED STUDY, European journal of cancer, 34, 1998, pp. 32-33
Authors:
VANHOE L
GRYSPEERDT S
BLOEMEN H
TIMMERMAN D
NEVEN P
MARCHAL G
VERGOTE I
Citation: L. Vanhoe et al., TAMOXIFEN-INDUCED CHANGES OF THE UTERUS - MRI FEATURES, European journal of cancer, 34, 1998, pp. 36-37
Authors:
PICCART MJ
GREEN J
LACAVE AJ
REED N
BENEDETTIPANICI P
LENTZ MA
SELVAIS R
CURRAN D
PINEL MC
VERGOTE I
Citation: Mj. Piccart et al., OXALIPLATIN - AN ACTIVE COMPOUND IN PLATINUM PRETREATED OVARIAN-CANCER PATIENTS - FINAL RESULTS OF A RANDOMIZED PHASE-II TRIAL BY THE EORTC- GYNECOLOGICAL CANCER COOPERATIVE GROUP, Annals of oncology, 9, 1998, pp. 314-314
Authors:
VANDAM P
DECLOEDT J
TJALMA W
PROVE A
VERGOTE I
Citation: P. Vandam et al., THE CONTRIBUTION OF DIAGNOSTIC LAPAROSCOPY IN ASSESSING THE OPERABILITY OF ADVANCED OVARIAN-CANCER, Annals of oncology, 9, 1998, pp. 336-336
Authors:
VERGOTE I
BERTELOOT P
VANGRAMBEREN M
ANDERSSON E
ROBERT J
BELLOTT R
Citation: I. Vergote et al., PHASE I-II STUDY OF DAUNOXOME (LIPOSOMAL DAUNORUBICIN) IN ASSOCIATIONWITH 5-FLUOROURACIL AND CYCLOPHOSPHAMIDE IN METASTATIC BREAST-CANCER, Annals of oncology, 9, 1998, pp. 657-657
Authors:
GRYSPEERDT S
VANHOE L
BOSMANS H
BAERT AL
VERGOTE I
MARCHAL G
Citation: S. Gryspeerdt et al., T2-WEIGHTED MR-IMAGING OF THE UTERUS - COMPARISON OF OPTIMIZED FAST SPIN-ECHO AND HASTE SEQUENCES WITH CONVENTIONAL FAST SPIN-ECHO SEQUENCES, American journal of roentgenology, 171(1), 1998, pp. 211-215
Authors:
NEVEN P
VERGOTE I
Citation: P. Neven et I. Vergote, SHOULD TAMOXIFEN USERS BE SCREENED FOR ENDOMETRIAL LESIONS, Lancet, 351(9097), 1998, pp. 155-157
Authors:
DALCIN P
TIMMERMAN D
VANDENBERGHE I
WANSCHURA S
KAZMIERCZAK B
VERGOTE I
DEPREST J
NEVEN P
MOERMAN P
BULLERDIEK J
VANDENBERGHE H
Citation: P. Dalcin et al., GENOMIC CHANGES IN ENDOMETRIAL POLYPS ASSOCIATED WITH TAMOXIFEN SHOW NO EVIDENCE FOR ITS ACTION AS AN EXTERNAL CARCINOGEN, Cancer research, 58(11), 1998, pp. 2278-2281
Authors:
TIMMERMAN D
DEPREST J
BOURNE T
VANDENBERGHE I
COLLINS WP
VERGOTE I
Citation: D. Timmerman et al., A RANDOMIZED TRIAL ON THE USE OF ULTRASONOGRAPHY OR OFFICE HYSTEROSCOPY FOR ENDOMETRIAL ASSESSMENT IN POSTMENOPAUSAL PATIENTS WITH BREAST-CANCER WHO WERE TREATED WITH TAMOXIFEN, American journal of obstetrics and gynecology, 179(1), 1998, pp. 62-70
Authors:
DECLOEDT J
BERTELOOT P
VERGOTE I
Citation: J. Decloedt et al., THE FEASIBILITY OF OPEN LAPAROSCOPY IN GYNECOLOGIC-ONCOLOGIC PATIENTS, Gynecologic oncology, 66(1), 1997, pp. 138-140
Authors:
VANHOE L
VANCUTSEM E
VERGOTE I
BAERT AL
BELLON E
DUPONT P
MARCHAL G
Citation: L. Vanhoe et al., SIZE QUANTIFICATION OF LIVER METASTASES IN PATIENTS UNDERGOING CANCER-TREATMENT - REPRODUCIBILITY OF ONE-, 2-DIMENSIONAL, AND 3-DIMENSIONALMEASUREMENTS DETERMINED WITH SPIRAL CT, Radiology, 202(3), 1997, pp. 671-675
Authors:
TIMMERMAN D
DEPREST J
VERGOTE I
Citation: D. Timmerman et al., TAMOXIFEN-INDUCED ENDOMETRIAL POLYP - REPLY, The New England journal of medicine, 336(19), 1997, pp. 1389-1390
Authors:
VANDIEST PJ
VANDAM P
HENZENLOGMANS SC
BERNS E
VANDERBURG MEL
GREEN J
VERGOTE I
Citation: Pj. Vandiest et al., A SCORING SYSTEM FOR IMMUNOHISTOCHEMICAL STAINING - CONSENSUS REPORT OF THE TASK-FORCE FOR BASIC RESEARCH OF THE EORTC-GCCG, Journal of Clinical Pathology, 50(10), 1997, pp. 801-804
Authors:
ASSIKIS VJ
NEVEN P
JORDAN VC
VERGOTE I
Citation: Vj. Assikis et al., A REALISTIC CLINICAL PERSPECTIVE OF TAMOXIFEN AND ENDOMETRIAL CARCINOGENESIS, European journal of cancer, 32A(9), 1996, pp. 1464-1476
Authors:
VANHOE L
VANCUTSEM E
VERGOTE I
MARCHAL G
BAERT AL
Citation: L. Vanhoe et al., REPORTING ON THE RESULTS OF CANCER-TREATMENT IN PATIENTS WITH METASTATIC LIVER-DISEASE - PROPOSAL OF SYMMETRICAL SIZE-DEPENDENT CT-CRITERIAFOR RESPONSE, Annals of oncology, 7(8), 1996, pp. 871-872
Authors:
GRYSPEERDT S
VANHOE L
BOSMANS H
KIEFER B
VERGOTE I
MARCHAL GJ
Citation: S. Gryspeerdt et al., ULTRAFAST T2-WEIGHTED MR-IMAGING OF THE FEMALE PELVIS - COMPARISON OFSINGLE-SHOT AND MULTISHOT TURBO SE SEQUENCES, Radiology, 201, 1996, pp. 1059-1059
Authors:
TIMMERMAN D
VERGOTE I
Citation: D. Timmerman et I. Vergote, TAMOXIFEN-INDUCED ENDOMETRIAL POLYP, The New England journal of medicine, 335(22), 1996, pp. 1650-1650
Authors:
TIMMERMAN D
MOERMAN P
VERGOTE I
Citation: D. Timmerman et al., MEIGS-SYNDROME WITH ELEVATED SERUM CA-125 LEVELS - 2 CASE-REPORTS ANDREVIEW OF THE LITERATURE, Gynecologic oncology, 59(3), 1995, pp. 405-408
Authors:
MAKAR AP
KAERN J
KRISTENSEN GB
VERGOTE I
BORMER OP
TROPE CG
Citation: Ap. Makar et al., EVALUATION OF SERUM CA-125 LEVEL AS A TUMOR-MARKER IN BORDERLINE TUMORS OF THE OVARY, International journal of gynecological cancer, 3(5), 1993, pp. 299-303
Risultati:
1-22
|